
The rush to secure doses of the antiviral remdesivir is unfounded as it has little or no impact on survival in those hospitalised with Covid-19, leading doctors and members of the state task force have said.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Q9eh17
via
IFTTT
0 comments:
Post a Comment